Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio (NASDAQ: PALI) announced the Japan Patent Office granted a composition-of-matter patent for PALI-2108, a gut-microbiota-activated PDE4 B/D inhibitor targeting fibrostenotic Crohn’s disease (FSCD) and moderate-to-severe ulcerative colitis (UC).

The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. PALI-2108 has completed Phase 1a SAD/MAD and FE studies, a Phase 1b cohort in UC, and is in an ongoing Phase 1b cohort in FSCD. Data are expected to support a Phase 2 IND submission in H1 2026. The patent expands the company’s global IP estate for its locally-acting PDE4 prodrug platform.

Palisade Bio (Nasdaq: PALI) appointed James Izanec, MD, AGAF as Vice President, Clinical Development effective Dec 2, 2025. Dr. Izanec is a physician‑scientist with over two decades of clinical and drug‑development leadership across immunology, neuroscience, and gastroenterology.

Key credentials cited: leadership of global Phase 2/3 programs including oversight of a 1,200‑patient Phase 3 Crohn’s program, strategic roles on ozanimod and deucravacitinib development, prior senior roles at Bristol Myers Squibb and Janssen, and principal‑investigator experience on more than 50 clinical trials.

Palisade Bio (Nasdaq: PALI) will present a live webcast fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 AM ET. CEO JD Finley and CMO Dr. Mitchell Jones will participate and management will be available for one-on-one in-person meetings with qualified, registered investors.

The webcast will be available on the company’s Investors > Events page at palisadebio.com, with a replay posted two hours after the live event and archived for 90 days.

Palisade Bio (NASDAQ: PALI) appointed Sharon Skare as Vice President, Global Head of Clinical Operations on Oct 28, 2025. Ms. Skare brings over 24 years of global clinical development and operations experience across autoimmune, metabolic, gastrointestinal, and fibrotic diseases.

The company is advancing PALI-2108, an orally administered, gut‑restricted prodrug designed to release a PDE4 inhibitor in the terminal ileum and colon. Palisade completed a Phase 1a/1b study with positive data, is conducting a Phase 1b study in fibrostenotic Crohn’s disease, and plans to submit Phase 2 INDs to the FDA in H1 2026. Management expects Skare’s experience in IBD operations and inspection readiness to support clinical and regulatory execution.

Palisade Bio (Nasdaq: PALI) announced first patients dosed in its open-label Phase 1b study of PALI-2108, an ileocolonic-targeted PDE4 inhibitor prodrug for fibrostenotic Crohn’s disease (FSCD), on Oct 20, 2025. The study will enroll ~6–12 patients to evaluate safety, tolerability, PK, PD, tissue pharmacology, and molecular responses over a 14-day dosing period. Topline safety, PK, and PD data are anticipated in Q1 2026. Data plus existing UC program results are planned to support a Phase 2 IND submission in H1 2026.

Palisade Bio (Nasdaq: PALI) announced that the Canadian Intellectual Property Office granted patent No. 3,174,137 for PALI-2108, titled “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors,” providing composition-of-matter protection through May 28, 2041. PALI-2108 is an orally administered, ileocolonic-targeted PDE4 B/D inhibitor designed for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC). The molecule uses a galactose-derived sugar moiety activated by colonic β-glucuronidase to enable colon-specific distribution with reduced systemic exposure, as shown in a tissue distribution study. Patient dosing in the Phase 1b FSCD study was expected in H2 2025, topline data expected in Q1 2026, and a planned Phase 2 IND submission to FDA is targeted for H1 2026.

Palisade Bio (Nasdaq: PALI) announced on October 9, 2025 that it has cancelled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on October 10, 2025. The meeting was earlier reconvened on September 26, 2025 but adjourned without business due to a lack of quorum.

The company said it still has not received sufficient proxies to constitute a quorum and has withdrawn from stockholder consideration the proposals included in its definitive proxy statement filed with the SEC on August 18, 2025.

Palisade Bio (Nasdaq: PALI) announced closing an upsized public offering on October 2, 2025 that raised approximately $138 million in gross proceeds, including full exercise of the underwriter’s over-allotment option. The offering comprised 197,154,844 shares at a public offering price of $0.70 per share. Proceeds will support the upcoming Phase 2 clinical program for PALI-2108 in ulcerative colitis. Ladenburg Thalmann served as sole book-running manager. SEC registration statements (Form S-1 File Nos. 333-290568 and 333-290644) were effective Sept 30 and Oct 1, 2025.

Palisade Bio (NASDAQ: PALI), a clinical-stage biopharmaceutical company, has announced the pricing of an upsized $120 million underwritten public offering. The offering consists of 171,440,559 shares of common stock priced at $0.70 per share.

The company has granted underwriters a 45-day option to purchase up to an additional 25,714,285 shares at the public offering price. Ladenburg Thalmann & Co. Inc. is serving as the sole book-running manager. The offering is expected to close around October 2, 2025, subject to customary closing conditions.